GlassScriptPhysician profile
Ara Thomassian
NPI 1609118777
$2,234.02
in general payments reported to CMS, 2019-2025
26 companies · $160 in 2025
The $160 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,434 · 2020: $303 · 2023: $118 · 2024: $219 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $693.82 | 2019-2025 | Tavneos, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $262.90 | 2019-2020 | |
| Lilly USA, LLC | $243.93 | 2019-2025 | Mounjaro, Zepbound |
| Philips North America LLC | $200.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $103.95 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.40 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $85.75 | 2019-2024 | Wegovy, Saxenda |
| Mallinckrodt Enterprises LLC | $60.86 | 2019 | |
| Abbvie INC. | $52.12 | 2023 | Qulipta |
| Astellas Pharma US INC | $50.25 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $42.35 | 2019-2020 | |
| Gilead Sciences, INC. | $41.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.56 | 2019 | |
| Opko Pharmaceuticals, LLC | $34.34 | 2019 | |
| Vertiflex, INC. | $25.57 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.99 | 2019 | |
| Bausch Health US, LLC | $23.99 | 2019 | |
| Exact Sciences Corporation | $19.89 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $19.75 | 2019 | |
| Genzyme Corporation | $18.14 | 2019 | |
| Fresenius USA Marketing, INC. | $16.87 | 2019 | |
| Merck Sharp & Dohme LLC | $16.37 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.03 | 2020 | |
| Genentech USA, INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ara Thomassian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.